Major Growth Driver Identified in 2025 Computer-Aided Drug Discovery Market: Prevalence Of Cancer Driving Growth In The Computer-Aided Drug Discovery Market

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Computer-Aided Drug Discovery Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In the past few years, the computer-assisted drug discovery market has seen significant growth. From $6.69 billion in 2024, it is expected to expand to $7.56 billion in 2025, marking a compound annual growth rate (CAGR) of 12.9%. Factors contributing to this upward trend during the historical period includes advancements in computational power, enhanced performance in molecular modeling, an increased demand from the pharmaceutical sector, regulatory bodies' support, and effective collaborations.

Computer-Aided Drug Discovery Market Size Forecast: What's the Projected Valuation by 2029?
In the coming years, rapid expansion is forecasted for the computer-aided drug discovery market, potentially reaching $12.19 billion in 2029 with a CAGR of 12.7%. This anticipated growth, during the forecast period, can be linked to factors such as the integration of Artificial Intelligence (AI) and Machine Learning (ML) in drug discovery procedures, the shift to personalized medicine, the rise in big data accessibility, and the development and adoption of cloud-based platforms specialized in computer-aided drug discovery. During this prediction timeframe, collaborative initiatives between various stakeholders, the growth of AI-centric platforms providing comprehensive solutions, and drug discovery not forgetting product innovations are some of the dominant trends expected.

View the full report here:
https://www.thebusinessresearchcompany.com/report/computer-aided-drug-discovery-global-market-report

What Are the Drivers Transforming the Computer-Aided Drug Discovery Market?
The increasing incidence of cancer is predicted to drive the expansion of the computer-aided drug discovery industry. Cancer is a collection of illnesses marked by the unchecked development and proliferation of aberrant cells within the body. Changes in lifestyle and urbanization, environmental contamination, consumption of tobacco and alcohol, health services accessibility, and knowledge are all contributing to the surging number of cancer diagnoses. Computer-assisted drug discovery can assist in creating medications that specifically target cancer cells with specific genetic alterations, leading the way towards more tailor-made and effective cancer treatments. For example, the National Cancer Institute, a United States-based cancer research and training organization, reported in May 2024 that nearly 20 million new cases and 9.7 million cancer-related deaths occurred in 2022. These numbers are predicted to significantly increase by 2040, with approximately 29.9 million new cases and 15.3 million deaths annually. Hence, the growing incidence of cancer is fuelling the computer-aided drug discovery market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19379&type=smp

What Long-Term Trends Will Define the Future of the Computer-Aided Drug Discovery Market?
Major firms in the computer-aided drug discovery (CADD) marketplace are making considerable strides in the innovation of solutions such as the use of artificial intelligence in drug discovery. This is aimed at improving the accuracy, pace, and effectiveness of identifying drug candidates, optimizing their primary components, and facilitating the creation of personalized treatments. Artificial Intelligence (AI) in this field involves the use of AI technologies like machine learning and deep learning, that utilize sophisticated algorithms to expedite and enhance the precision of new drug discovery and development. An excellent example is Merck KGaA, a German-based science, and technology firm that, in December 2023, introduced AIDDISONTM, the debut software-as-a-service platform integrating drug discovery with synthesis. By integrating generative AI, machine learning, and computer-aided drug design, AIDDISONTM expedites the drug development process by virtually screening compounds from an inventory of over 60 billion chemical targets and suggesting the best synthesis paths. The platform, which is trained with two decades of pharmaceutical R&D data, can identify potential drugs with desirable properties such as non-toxicity and stability. With the inclusion of Merck's SynthiaTM retrosynthesis API, AIDDISONTM enhances the efficiency and sustainability of drug manufacturing, with the ultimate aim of curtailing the cost and duration of drug discovery.

Which Segments in the Computer-Aided Drug Discovery Market Offer the Most Profit Potential?
The computer-aided drug discoverymarket covered in this report is segmented -

1) By Type: Structure Based Drug Design, Ligand-Based Drug Design, Sequence-Based Approaches
2) By Therapeutic Area: Oncology, Neurology, Cardiovascular Disease, Respiratory Disease, Diabetes, Other Therapeutic Areas
3) By End User: Pharmaceutical Companies, Biotechnology Companies, Research Laboratories

Subsegments:
1) By Structure Based Drug Design: X-ray Crystallography, Nuclear Magnetic Resonance (NMR) Spectroscopy, Molecular Docking Studies, Virtual Screening
2) By Ligand-Based Drug Design: Quantitative Structure-Activity Relationship (QSAR) Models, Pharmacophore Modeling, Ligand Similarity Searching, Fragment-Based Drug Design
3) By Sequence-Based Approaches: Protein Structure Prediction, Homology Modeling, Bioinformatics for Drug Target Identification, Genomic Data Analysis for Drug Discovery

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=19379&type=smp

Which Firms Dominate the Computer-Aided Drug Discovery Market by Market Share and Revenue in 2025?
Major companies operating in the computer-aided drug discovery market are Dassault Systèmes SE, PerkinElmer Inc., Roivant Sciences Ltd., Certara Inc., Schrödinger Inc., XtalPi Inc., Dotmatics Limited, Simulations Plus Inc., ChemAxon Ltd., Exscientia Ltd., Insilico Medicine Inc., Collaborative Drug Discovery Inc., OpenEye Scientific Software Inc., Nimbus Therapeutics LLC, Atomwise Inc., GNS Healthcare Inc., BenevolentAI Limited, EpiVax Inc., Numerate Inc., Cloud Pharmaceuticals Inc., Aris Pharmaceuticals Inc., Cyclica Inc., BioSolveIT GmbH, Chemical Computing Group ULC, InSilicoTrials Technologies S.p.A

Which Regions Offer the Highest Growth Potential in the Computer-Aided Drug Discovery Market?
North America was the largest region in the computer-aided drug discovery (CADD) market in 2024. The regions covered in the computer-aided drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19379

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.